Bachrodt Amy 4

4 · Maze Therapeutics, Inc. · Filed Apr 2, 2026

AI-generated summary of this filing

Updated Apr 2, 2026

Maze Therapeutics (MAZE) SVP Amy Bachrodt Exercises Options, Sells Shares

What Happened

Amy Bachrodt, SVP Finance at Maze Therapeutics, exercised options to acquire 2,500 shares at $10.42 each (cost $26,050) on April 1, 2026. On the same day she sold 2,200 shares at a weighted average $29.32 and 300 shares at a weighted average $30.34, receiving total gross proceeds of about $73,611. The Form 4 also shows a disposition of 2,500 shares at $0 (reported as a derivative disposition).

Key Details

Transaction date: April 1, 2026; Form 4 filed April 2, 2026 (timely).
Option exercise: 2,500 shares acquired at $10.42 for $26,050.
Open-market sales: 2,200 shares at $29.32 (weighted avg; prices ranged $28.85–$29.82) for $64,510; 300 shares at $30.34 (weighted avg; ranged $30.05–$30.50) for $9,101. Total gross sales ≈ $73,611.
Derivative disposition: 2,500 shares reported disposed at $0. (This entry is shown separately on the Form 4 and is commonly used when shares are surrendered/withheld in connection with an option exercise or tax/withholding obligations.)
Footnotes: One sale was executed under a Rule 10b5-1 trading plan adopted Sept 29, 2025 (F1). Vesting schedule noted: options vest 1/48th monthly beginning Jan 1, 2025 (F4).
Shares owned after transaction: not reported in the provided excerpt of the filing.

Context

This was an option exercise combined with immediate open-market sales. The exercise at $10.42 followed by sales near $29–$30 resulted in a material spread between strike and sale prices; proceeds from the sales were about $73.6K. The presence of a 10b5-1 plan note indicates at least some sales were pre-planned rather than discretionary.

Form 4

Period: 2026-04-01

SVP, Finance

Transactions

Exercise/Conversion
Common Stock
[F1]
2026-04-01$10.42/sh+2,500$26,050→ 15,465 total
Sale
Common Stock
[F1][F2]
2026-04-01$29.32/sh−2,200$64,510→ 13,265 total
Sale
Common Stock
[F1][F3]
2026-04-01$30.34/sh−300$9,101→ 12,965 total
Exercise/Conversion
Stock Option (Right to Buy)
[F1][F4]
2026-04-01−2,500→ 33,833 total
Exercise: $10.42Exp: 2034-12-08→ Common Stock (2,500 underlying)

Footnotes (4)

[F1]This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025.
[F2]The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.85 to $29.82 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and in footnote 3 of this Form 4.
[F3]The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.05 to $30.50 per share, inclusive.
[F4]The option vested or vests as to 1/48th of the total award monthly, with the first tranche vested on January 1, 2025, and each subsequent tranche vesting on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date.

Signature

/s/ Courtney Phillips, as attorney-in-fact|2026-04-02

1 file